Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Reason given: Due to lack of efficacy shown at the time of the interim analysis.
Key facts
- Where
- Lyon, Marseille, Paris, Saint-Herblain, and Toulouse, FranceSee the 6 sites
- Phase
- Phase 1
Where in France
- Centre Leon BerardLyon, FranceNo longer taking part
- Hôpitaux Universitaires de Marseille TimoneMarseille, FranceNo longer taking part
- Hopital Saint LouisParis, FranceNo longer taking part
- Institut Gustave RoussyParis, FranceNo longer taking part
- Institut de Cancérologie de l'OuestSaint-Herblain, FranceNo longer taking part
- Institut Claudius RegaudToulouse, FranceNo longer taking part
Trial details
- Who runs it
- SOTIO Biotech AG
- Trial code
- NCT04234113
- Record updated
- 27 March 2026
- Original description
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumorsRead full original descriptionShow less
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Inclusion: Patients with selected histologically or cytologically confirmed advanced and/or metastatic solid tumors who are refractory to or intolerant of existing therapies known to provide clinical benefit for their condition; ECOG performance score 0-1. Patients with ECOG performance score 2 to be discussed with the sponsor's medical monitor to be agreed for inclusion; Estimated life expectancy of ≥3 months; Washout periods: 4 weeks for chemotherapy, 4 weeks or 5 half-lives (whichever shorter) for biologic agents including immuno-oncology therapy and 4 weeks from major surgeries, definitive radiotherapy and 2 weeks after palliative radiotherapy; At least one measurable lesion per iRECIST in a non-irradiated port. If in a previously irradiated port, must have demonstrated progression since best response to radiation therapy; Have fully recovered from previous treatment to grade ≤1 toxicity (excluding alopecia) or have stable grade 2 neuropathy; Adequate organ system function; Negative serum pregnancy test, if woman of child-bearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized); Accessible tumor tissue available for fresh biopsy.
Exclusion: Has received a live vaccine within 30 days of planned start of study therapy; Known additional malignancy that is progressing and/or requires active treatment; History of and current interstitial lung disease or fibrosis and pneumonitis; patients with clinically significant or oxygen requiring chronic obstructive pulmonary disease or any chronic inflammatory disease (sarcoidosis etc.); Any active autoimmune disease or a documented history of autoimmune disease, poorly controlled asthma, or history of syndrome that required systemic steroids (except the allowed doses) or immunosuppressive medications, except for patients with vitiligo or resolved childhood asthma/atopy; Parts B and B1:; Is hypersensitive to any of the ingredients of pembrolizumab drug product (KEYTRUDA®); History of solid organ transplantation or hematopoietic stem cell transplantation; Prior exposure to drugs that are agonists of IL-2- or IL-15-like but not limited to rhIL-15 (NCI), ALT-803 (ALTOR), NKTR-214 (Nektar); Absolute white blood cell count ≤2.0 ×10e9/L; Absolute neutrophil count ≤1.0 ×10e9/L; Platelet count ≤100×10e9/L; Untreated central nervous system metastases and/or leptomeningeal carcinomatosis; Pregnant or breastfeeding women; Specific co-morbidities.